Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 3 2Phase 2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia 1

Interventions

pembrolizumab 524Specimen Handling 383Carboplatin 377Magnetic Resonance Spectroscopy 336Cisplatin 332Nivolumab 308Cyclophosphamide 298Radiotherapy 257Paclitaxel 255Gemcitabine 235Biopsy 235Bevacizumab 218Dexamethasone 169durvalumab 168Oxaliplatin 163Capecitabine 158Rituximab 157Fluorouracil 149venetoclax 147Docetaxel 147Etoposide 142Drug Therapy 142atezolizumab 141Doxorubicin 134Ipilimumab 129Radiosurgery 120Prednisone 120Lenalidomide 119Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × quizartinib × 1 year × Clear all
NCT04107727 2026-03-24

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

PETHEMA Foundation

Phase 2 Completed
273 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06824168 2025-12-04

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Daiichi Sankyo

Phase 2 Recruiting
130 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡